Sumnary A new two-phase test kit for faecal occult blood combining a sensitive guaiac test (Fecatwin (S)ensitive) with an immunological test for human haemoglobin (FECA-EIA) was compared with three current guaiac tests (Fecatest, Fecatwin, Haemoccult) 
Sumnary A new two-phase test kit for faecal occult blood combining a sensitive guaiac test (Fecatwin (S)ensitive) with an immunological test for human haemoglobin (FECA-EIA) was compared with three current guaiac tests (Fecatest, Fecatwin, Haemoccult) The detection of colorectal cancer in asymptomatic patients has been accepted as the only effective way of improving the prognosis of this disease (Greegor, 1967; Bassett & Goulston, 1978; Goulston & Davidson, 1980) . In large scale screening studies faecal occult blood testing (FOBT) based on a nonspecific guaiac test has given reasonably good results in asymptomatic patients (Gnauck, 1974; Gilbertsen et al., 1980; Winawer et al., 1980; Blum et al., 1983) .
The vulnerability of current FOBTs to peroxidase and pseudoperoxidase activity in food has been widely recognized (Illingworth, 1965; Wiener & Wiener, 1975; Bassett & Goulston, 1980; . False positive results lessen the usefulness of the tests, resulting in unnecessary examinations and unwanted increases in costs. False negative results are obtained because the tests are not sufficiently sensitive. Slight bleeding of low degree from small cancers or adenomas is therefore not always detected (Gnauck, 1974; Kruis et al., 1979; Winawer et al., 1982) .
The above-mentioned shortcomings of the current FOBTs have been the main reasons for the development of tests for specific detection of human blood in stools. All these tests are based on the identification of human haemoglobin (Hb) in stools. Human Hb has been identified by means of haemagglutination inhibition (Adams & Layman, 1974; Heinrich, 1982) , radial immunodiffusion (Barrows et al., 1976) , inhibition of anti-Rh 29 by erythrocyte stroma (Rosenfield et al., 1978) and immunofluorescence (Vellacott et al., 1981 The age of the 19 colorectal cancer patients was 67 + 9 years (mean + s.d.) and that of the 11 controls 58+16 years. The mean delay between the first symptoms and surgery for the colorectal cancer patients was 7.2+5.0 months. The first symptoms of colorectal cancer were in decreasing frequency changes in bowel habits (n = 8), abdominal pain (n = 5), anaemia (n = 4), and blood in the faeces (n = 2). Of the cancer patients 5 had a tumour in the rectum, 8 in the left hemicolon and 6 in the right hemicolon. Two patients had 2 primary colorectal cancers. Of the 19 colorectal malignancies 9 were stage A (47%), 3 were B (16%), 4 were C (21%) and 3 were stage D (16%).
Any manipulation of the tumour such as biopsy or administration of a barium enema was strictly avoided for one week prior to faecal collection in order to avoid induction of bleeding. None of the patients in the series had any history of previous upper gastro-intestinal tract disease.
Information concerning testing and diet was given both orally and in writing to the subjects studied. The study delayed surgery for the cancer patients for 5-7 days. This problem was discussed with the ethical committee of the hospital. It was decided that the faecal collection should start 2 days after the administration of the 51Cr-labelled erythrocytes (Davies, 1971; Friedman, 1972) and that only one or two 48h faecal collections should be performed in order to delay the operation as little as possible.
The diagnosis of colorectal cancer was confirmed histologically in all the patients. The tumour specimens were classified according to the modified Dukes' method (Dukes, 1932; Turnbull et al., 1967) .
The restricted diet excluded any food containing animal blood, uncooked fish, tomatoes, ketchup, paprika, radish, horse-radish, turnips, bananas, cherries, cortisone, vitamin C, aspirin and other drugs for headache and the common cold. The diet was started 3 days prior to the faecal collection and was continued throughout the experimental period. One subject had not followed the diet before the postoperative sample was taken.
The faecal samples were collected in plastic containers with airtight caps and with a central hollow to increase counting efficiency. After collection, the 48h samples were homogenized and the 5 occult blood tests were made randomly and without knowledge of the quantitative test results. Samples for the FECA-EIA had to be stored at -20°C until analysed. It was found that a 6-month period of storage did not change the results.
Fecatest, Fecatwin (S)ensitive, Fecatwin with an FP-901 photometer (Labsystems 9-channel batch processing analyser designed to read Labsystems EIA-grade cuvette blocks). 8. The colour intensity is directly related to the concentration of Hb in the patient specimen. The specificity of anti-human haemoglobin used as both capture and second antibody was tested with ELISA. Cow, chicken, and rabbit haemoglobins were tested and the only crossreaction detected was that with rabbit haemoglobin. The details of the method will be described elsewhere (Partanen et al., unpublished) . In the present study both a prototype and the final kit were used.
The (Table II) . There was also a significant correlation between the Dukes' stage and the daily blood loss when A and B stage cancers were compared with C and D stage cancers (Table II) .
Discussion
The concept put forward by Greegor (1967) that detection of faecal occult blood in asymptomatic patients leads to earlier diagnosis of colorectal cancer has now been widely accepted as a prerequisite for improved prognosis (Gnauck, 1974; Bassett & Goulston, 1978; Gilbertsen et al., 1980; Winawer et al., 1982) . Favourable results in colorectal cancer screening have also been reported using colonoscopy and sigmoidoscopy (Gilbertsen, 1974; Winawer et al., 1978; Kruis et al., 1979) . Gilbertsen (1974) reported a decrease in rectal (Gnauck, 1974; Gilbertsen et al., 1980; Winawer et al., 1980) . Most of the current FOBTs are based on the guaiac test, giving false negative results in 9-31% and false positive results in 2-20% (Gnauck, 1974; Bassett & Goulston, 1978; Kruis et al., 1979; Gilbertsen et al., 1980; Winawer et al., 1980 Winawer et al., , 1982 Doran & Hardcastle, 1982; . The combined Fecatwin S-FECA-EIA kit aims at eliminating all false positive results. Because the FECA-EIA test is comparatively expensive, it is suggested that only the Fecatwin S positive samples should be investigated with the FECA-EIA test. However, this will lead to some false negative test results, which in our cancer material would have amounted to 13% of the single tests because 10% of the samples were negative with Fecatwin S and 3% negative with FECA-EIA. Fecatest gave a corresponding false negative rate of 7% and both the sensitive tests had a sensitivity limit as low as 1.2-1.7mg Hbg-1 faeces. There seems to be no significant difference in sensitivity between Fecatwin S and the original Fecatest (Adlercreutz et al., 1982) . Haemoccult and Fecatwin were found to be much less sensitive, giving 23% false negative single test results. The difference was probably not due to homogenization of the faeces, which was necessary in order to get comparable results, because in a previous study the difference was larger when non-homogenized samples were studied (Adlercreutz et al., 1982 and in press) . Quite recently Doran et al. (1982) reported a 30% false negative rate for Haemoccult using the standard 3-day regimen. False negative results with Haemoccult still occurred in 10% after a 6-day test period. The most sensitive FOBTs all need a very strict peroxidase-free diet (Gnauck, 1974; Morris et al., 1976; Adlercreutz et al., 1978; . Because dietary restrictions seem to be difficult for patients to follow, even under controlled circumstances, as in our study, the human haemoglobin specific test appears to be mandatory in colorectal cancer screening.
Anaemia and melaena are common clinical signs of cancer of the right hemicolon. In the present study the faecal samples from patients with cancer in the right hemicolon were found to contain more blood than those from patients with cancer in the left hemicolon and rectum. A statistically significant correlation between the daily blood loss and the tumour stage was also observed. Similar results have been reported previously by .
In a trial by Songster et al. (1980) 29% of the colorectal cancer patients did not show bleeding by either the relatively insensitive immunological method of Barrows et al. (1976) In the present study 20% of the cancer patients had a blood loss of <2.7mgHbg-1 faeces. In these patients with slight bleeding, FECA-EIA was the only test giving 100% positive results. Measured with the "Cr method the sensitivity limit for FECA-EIA was 0.7mg Hb g-1 faeces. However, this is below the true sensitivity limit of the 51Cr method because at the level most of the radioactivity is due to biliary excretion of 5"Cr (Stephens & Lawrenson, 1969) . Thus, in vivo sensitivity of FECA-EIA cannot be determined exactly because no sufficiently sensitive reference method is available. In vitro the FECA-EIA test detects 0.01-.05mgHb added to 1 g of faeces. The immunological test therefore seems to be at least 10 times more sensitive than the guaiac screening test.
The test used for screening, in this case Fecatwin S, must be as sensitive as possible in order not to give false negative test results. This guaiac test is sensitive, but it was still negative in 10% of the samples (10.5% of the colorectal cancer patients) when testing only one or two samples from each subject. Despite this, we still recommend the use of the combined Fecatwin S and FECA-EIA kit and not the FECA-EIA test alone for screening because FECA-EIA, being a non-isotopic immunoassay, is relatively expensive. Using Fecatwin S as a screening test, only ,5-15% of the samples need to be retested with FECA-EIA, depending on the diet of the population screened. The present study was not aimed at investigating the usefulness of the combined kit for screening purposes, but at comparing the test with a reference method in normal subjects and in colorectal cancer patients, and at determining its sensitivity and accuracy. In our hands the immunological test proved to be both accurate and sensitive. We suggest that three consecutive samples be taken for screening purposes, because in this way the percentage of false negative results shown by Fecatwin S and caused by non-uniform distribution of blood in the faeces (Rosenfield et al., 1978) will probably be reduced to <5%.
It is concluded that the new two-phase test for occult blood in faeces is the first practical kit available and has great potential in colorectal cancer screening. No dietary restrictions are needed, which will increase patient compliance. Used in the suggested way, the test will probably lead to a good cost-benefit ratio. Further studies under field conditions are necessary before a final evaluation of this test is possible.
